{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:28:37Z","timestamp":1793896117424,"version":"4.8.0"},"reference-count":112,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","award":["BT\/PR58968\/BMS\/85\/1339\/2025"],"award-info":[{"award-number":["BT\/PR58968\/BMS\/85\/1339\/2025"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.tips.2025.11.004","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T13:11:30Z","timestamp":1765199490000},"page":"1283-1302","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Siglecs in immunotherapy: current clinical landscape and prospects"],"prefix":"10.1016","volume":"47","author":[{"given":"Abhinav","family":"Purohit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishaan","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratik S.","family":"Bhojnagarwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean D.","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Joseph","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3485-8369","authenticated-orcid":false,"given":"Devivasha","family":"Bordoloi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2025.11.004_bb0005","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/s41577-021-00617-9","article-title":"Checkpoint blockade: the end of the beginning","volume":"21","author":"Wolchok","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tips.2025.11.004_bb0010","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.tips.2025.11.004_bb0015","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.ymthe.2025.04.008","article-title":"DNA-based immunotherapy for cancer: in vivo approaches for recalcitrant targets","volume":"33","author":"Bhojnagarwala","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tips.2025.11.004_bb0020","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.tips.2025.11.004_bb0025","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/ejh.14101","article-title":"Antigen loss following CAR-T cell therapy: mechanisms, implications, and potential solutions","volume":"112","author":"Mishra","year":"2024","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.tips.2025.11.004_bb0030","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nri3737","article-title":"Siglec-mediated regulation of immune cell function in disease","volume":"14","author":"Macauley","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tips.2025.11.004_bb0035","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1146\/annurev-immunol-102419-035900","article-title":"Siglecs as immune cell checkpoints in disease","volume":"38","author":"Duan","year":"2020","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.tips.2025.11.004_bb0040","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.790317","article-title":"Siglec signaling in the tumor microenvironment","volume":"12","author":"van Houtum","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tips.2025.11.004_bb0045","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.tips.2009.02.005","article-title":"Siglecs as targets for therapy in immune-cell-mediated disease","volume":"30","author":"O'Reilly","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.tips.2025.11.004_bb0050","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.2174\/092986711796642580","article-title":"High-affinity ligands of Siglec receptors and their therapeutic potentials","volume":"18","author":"Magesh","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.tips.2025.11.004_bb0055","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1089\/omi.2009.0148","article-title":"The sialome \u2013 far more than the sum of its parts","volume":"14","author":"Cohen","year":"2010","journal-title":"OMICS"},{"key":"10.1016\/j.tips.2025.11.004_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2022.101140","article-title":"Impact of Siglecs on autoimmune diseases","volume":"90","author":"Brzezicka","year":"2023","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.tips.2025.11.004_bb0065","doi-asserted-by":"crossref","first-page":"R129","DOI":"10.1186\/ar2018","article-title":"Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren's syndrome: an open-label phase I\/II study","volume":"8","author":"Steinfeld","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.tips.2025.11.004_bb0070","doi-asserted-by":"crossref","first-page":"R74","DOI":"10.1186\/ar1942","article-title":"Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus","volume":"8","author":"Dorner","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.tips.2025.11.004_bb0075","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.jaci.2021.12.772","article-title":"An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria","volume":"149","author":"Altrichter","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.tips.2025.11.004_bb0080","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1158\/2326-6066.CIR-22-0366","article-title":"Targeting the Siglec-sialic acid immune axis in cancer: current and future approaches","volume":"10","author":"Laubli","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.tips.2025.11.004_bb0085","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2026102118","article-title":"Probing the binding specificities of human Siglecs by cell-based glycan arrays","volume":"118","author":"Bull","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2025.11.004_bb0090","first-page":"1178","article-title":"Siglecs as therapeutic targets in cancer","volume":"10","author":"Lim","year":"2021","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.tips.2025.11.004_bb0095","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nri2056","article-title":"Siglecs and their roles in the immune system","volume":"7","author":"Crocker","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tips.2025.11.004_bb0100","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1146\/annurev-immunol-020711-075018","article-title":"Siglecs and immune regulation","volume":"30","author":"Pillai","year":"2012","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.tips.2025.11.004_bb0105","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nri2014","article-title":"Activating and inhibitory functions of DAP12","volume":"7","author":"Turnbull","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tips.2025.11.004_bb0110","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1042\/BST0361467","article-title":"Siglecs as positive and negative regulators of the immune system","volume":"36","author":"Crocker","year":"2008","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.tips.2025.11.004_bb0115","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.tibs.2016.03.007","article-title":"Sialic acid mimetics to target the sialic acid-Siglec axis","volume":"41","author":"Bull","year":"2016","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.tips.2025.11.004_bb0120","doi-asserted-by":"crossref","first-page":"12402","DOI":"10.1073\/pnas.1304888110","article-title":"CD22 ligand-binding and signaling domains reciprocally regulate B-cell Ca2+ signaling","volume":"110","author":"Muller","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2025.11.004_bb0125","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41416-020-01126-7","article-title":"Insights into the role of sialylation in cancer progression and metastasis","volume":"124","author":"Dobie","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.tips.2025.11.004_bb0130","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.tips.2025.11.004_bb0135","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2107424118","article-title":"Siglecs-7\/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity","volume":"118","author":"Ibarlucea-Benitez","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2025.11.004_bb0140","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/s41467-021-21550-4","article-title":"Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9","volume":"12","author":"Rodriguez","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2025.11.004_bb0145","doi-asserted-by":"crossref","DOI":"10.1172\/JCI180282","article-title":"Sialylated glycoproteins suppress immune cell killing by binding to Siglec-7 and Siglec-9 in prostate cancer","volume":"134","author":"Wen","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tips.2025.11.004_bb0150","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007099","article-title":"Siglec-9(+) tumor-associated macrophages delineate an immunosuppressive subset with therapeutic vulnerability in patients with high-grade serous ovarian cancer","volume":"11","author":"Wang","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.tips.2025.11.004_bb0155","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s42003-024-06087-8","article-title":"Pancreatic cancer-associated fibroblasts modulate macrophage differentiation via sialic acid-Siglec interactions","volume":"7","author":"Boelaars","year":"2024","journal-title":"Commun. Biol."},{"key":"10.1016\/j.tips.2025.11.004_bb0160","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41423-024-01142-0","article-title":"Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibits anticancer immunity via CCL2","volume":"21","author":"Wieboldt","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.tips.2025.11.004_bb0165","doi-asserted-by":"crossref","first-page":"5085","DOI":"10.1182\/bloodadvances.2025015980","article-title":"Targeting Siglec-sialic acid checkpoint to reverse immune dysfunction mediated by plasmacytoid dendritic cells in myeloma","volume":"9","author":"Ray","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.tips.2025.11.004_bb0170","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2215376120","article-title":"MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint","volume":"120","author":"Smith","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2025.11.004_bb0175","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/ni1480","article-title":"Siglec-G is a B1 cell-inhibitory receptor that controls expansion and calcium signaling of the B1 cell population","volume":"8","author":"Hoffmann","year":"2007","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.tips.2025.11.004_bb0180","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.4049\/jimmunol.1401723","article-title":"Siglecs induce tolerance to cell surface antigens by BIM-dependent deletion of the antigen-reactive B cells","volume":"193","author":"Macauley","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.tips.2025.11.004_bb0185","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adh4379","article-title":"Siglec-7 glyco-immune binding mAbs or NK cell engager biologics induce potent antitumor immunity against ovarian cancers","volume":"9","author":"Bordoloi","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.tips.2025.11.004_bb0190","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/14712598.2020.1822318","article-title":"Anti-CD20 treatment for B-cell malignancies: current status and future directions","volume":"21","author":"Klein","year":"2021","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.tips.2025.11.004_bb0195","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev-immunol-083122-044829","article-title":"B cell-directed therapy in autoimmunity","volume":"42","author":"Abeles","year":"2024","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.tips.2025.11.004_bb0200","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004850","article-title":"Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia","volume":"10","author":"Cyr","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.tips.2025.11.004_bb0205","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1182\/blood.2020009192","article-title":"Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia","volume":"138","author":"Jetani","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.tips.2025.11.004_bb0210","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1038\/s41467-024-48678-3","article-title":"Siglec-6 as a therapeutic target for cell migration and adhesion in chronic lymphocytic leukemia","volume":"15","author":"Nunes","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2025.11.004_bb0215","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1158\/2326-6066.CIR-18-0102","article-title":"Siglec-6 on chronic lymphocytic leukemia cells is a target for post-allogeneic hematopoietic stem cell transplantation antibodies","volume":"6","author":"Chang","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.tips.2025.11.004_bb0220","doi-asserted-by":"crossref","first-page":"4494","DOI":"10.1182\/blood-2009-05-222786","article-title":"A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display","volume":"114","author":"Baskar","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.tips.2025.11.004_bb0225","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \"biological missile\" for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.tips.2025.11.004_bb0230","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study","volume":"125","author":"Kantarjian","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.tips.2025.11.004_bb0235","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/sj.bmt.1704201","article-title":"Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias","volume":"32","author":"Burke","year":"2003","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.tips.2025.11.004_bb0240","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/cncr.28136","article-title":"Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia","volume":"119","author":"Kantarjian","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.tips.2025.11.004_bb0245","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/leu.2017.187","article-title":"Gemtuzumab ozogamicin in acute myeloid leukemia","volume":"31","author":"Godwin","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.tips.2025.11.004_bb0250","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12943-024-01963-7","article-title":"A review of the clinical efficacy of FDA-approved antibody\u2013drug conjugates in human cancers","volume":"23","author":"Liu","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.tips.2025.11.004_bb0255","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1158\/1535-7163.MCT-23-0506","article-title":"ADCT-602, a novel PBD dimer-containing antibody-drug conjugate for treating CD22-positive hematologic malignancies","volume":"23","author":"Zammarchi","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.tips.2025.11.004_bb0260","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/561814","article-title":"A humanized anti-CD22-onconase antibody-drug conjugate mediates highly potent destruction of targeted tumor cells","volume":"2015","author":"Weber","year":"2015","journal-title":"J Immunol Res"},{"key":"10.1016\/j.tips.2025.11.004_bb0265","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/s41589-020-0622-x","article-title":"Targeted glycan degradation potentiates the anticancer immune response in vivo","volume":"16","author":"Gray","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.tips.2025.11.004_bb0270","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.pharmthera.2017.12.002","article-title":"Bispecific antibodies for cancer therapy: a review","volume":"185","author":"Krishnamurthy","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.tips.2025.11.004_bb0275","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10651","article-title":"Siglec15\/TGF-beta bispecific antibody mediates synergistic anti-tumor response against 4T1 triple negative breast cancer in mice","volume":"9","author":"Shen","year":"2024","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.tips.2025.11.004_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.136635","article-title":"A bispecific antibody targeting the Ig domains of Siglec-E displays enhanced antitumor effects","volume":"281","author":"Zhao","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.tips.2025.11.004_bb0285","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/icb.2014.93","article-title":"Bispecific T-cell engagers for cancer immunotherapy","volume":"93","author":"Huehls","year":"2015","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.tips.2025.11.004_bb0290","article-title":"Antibody-lectin chimeras for glyco-immune checkpoint blockade","author":"Stark","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.tips.2025.11.004_bb0295","doi-asserted-by":"crossref","DOI":"10.1172\/JCI162593","article-title":"Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing","volume":"134","author":"Appelbaum","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tips.2025.11.004_bb0300","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.161563","article-title":"ST6GAL1 sialyltransferase promotes acinar to ductal metaplasia and pancreatic cancer progression","volume":"8","author":"Bhalerao","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.tips.2025.11.004_bb0305","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.trecan.2023.11.009","article-title":"Targeting myeloid cells for cancer immunotherapy: Siglec-7\/9\/10\/15 and their ligands","volume":"10","author":"Boelaars","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.tips.2025.11.004_bb0310","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41375-024-02454-w","article-title":"The glycosyltransferase ST3GAL4 drives immune evasion in acute myeloid leukemia by synthesizing ligands for the glyco-immune checkpoint receptor Siglec-9","volume":"39","author":"Krishnamoorthy","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.tips.2025.11.004_bb0315","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1182\/bloodadvances.2021006805","article-title":"Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell-mediated tumor responses","volume":"6","author":"Daly","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.tips.2025.11.004_bb0320","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1021\/acschembio.8b01018","article-title":"Exploiting CD22 to selectively tolerize autoantibody producing B-cells in rheumatoid arthritis","volume":"14","author":"Bednar","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.tips.2025.11.004_bb0325","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1172\/JCI125456","article-title":"CD33 recruitment inhibits IgE-mediated anaphylaxis and desensitizes mast cells to allergen","volume":"129","author":"Duan","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tips.2025.11.004_bb0330","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.actbio.2021.07.063","article-title":"Sialic acid conjugate-modified liposomes enable tumor homing of epirubicin via neutrophil\/monocyte infiltration for tumor therapy","volume":"134","author":"Ding","year":"2021","journal-title":"Acta Biomater."},{"key":"10.1016\/j.tips.2025.11.004_bb0335","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2012408118","article-title":"Modulation of immune cell reactivity with cis-binding Siglec agonists","volume":"118","author":"Delaveris","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2025.11.004_bb0340","doi-asserted-by":"crossref","first-page":"9302","DOI":"10.1021\/jacs.2c00922","article-title":"Suppressing immune responses using Siglec ligand-decorated anti-receptor antibodies","volume":"144","author":"Islam","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.tips.2025.11.004_bb0345","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.3390\/cancers15133346","article-title":"Acute lymphoblastic leukemia immunotherapy treatment: now, next, and beyond","volume":"15","author":"Aureli","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.tips.2025.11.004_bb0350","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.3324\/haematol.2023.284409","article-title":"Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22(+) acute lymphoblastic leukemia: results of the phase IB ITCC-059 trial","volume":"109","author":"Pennesi","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.tips.2025.11.004_bb0355","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1200\/JCO.21.01693","article-title":"Phase II trial of inotuzumab ozogamicin in children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukemia: Children's Oncology Group Protocol AALL1621","volume":"40","author":"O'Brien","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tips.2025.11.004_bb0360","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1200\/JCO.24.00490","article-title":"Inotuzumab ozogamicin and low-intensity chemotherapy in older patients with newly diagnosed CD22(+) Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia","volume":"42","author":"Chevallier","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tips.2025.11.004_bb0365","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1038\/s41375-019-0488-7","article-title":"CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia","volume":"33","author":"Pan","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.tips.2025.11.004_bb0370","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2025.11.004_bb0375","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41591-021-01326-5","article-title":"Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells","volume":"27","author":"Singh","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2025.11.004_bb0380","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011549","article-title":"CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy","volume":"13","author":"Myers","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.tips.2025.11.004_bb0385","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/s41375-024-02220-y","article-title":"CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results","volume":"38","author":"Schultz","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.tips.2025.11.004_bb0390","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13045-020-00856-8","article-title":"Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia","volume":"13","author":"Dai","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.tips.2025.11.004_bb0395","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2025.11.004_bb0400","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.tips.2025.11.004_bb0405","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood.2019000017","article-title":"Efficacy and safety of CAR19\/22 T-cell cocktail therapy in patients with refractory\/relapsed B-cell malignancies","volume":"135","author":"Wang","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.tips.2025.11.004_bb0410","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood.2019003293","article-title":"Sequential CD19-22 CAR T therapy induces sustained remission in children with r\/r B-ALL","volume":"135","author":"Pan","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.tips.2025.11.004_bb0415","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S1470-2045(23)00436-9","article-title":"Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study","volume":"24","author":"Pan","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tips.2025.11.004_bb0420","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1182\/blood.2024024952","article-title":"A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia","volume":"144","author":"Srinagesh","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.tips.2025.11.004_bb0425","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1158\/1078-0432.CCR-20-3863","article-title":"CRISPR\/Cas9-engineered universal CD19\/CD22 dual-targeted CAR-T cell therapy for relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"27","author":"Hu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tips.2025.11.004_bb0430","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/10428190009060322","article-title":"Phase I\/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma","volume":"38","author":"Vose","year":"2000","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.tips.2025.11.004_bb0435","first-page":"3995S","article-title":"Final results of a phase I radioimmunotherapy trial using (186)Re-epratuzumab for the treatment of patients with non-Hodgkin's lymphoma","volume":"9","author":"Postema","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tips.2025.11.004_bb0440","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1158\/1078-0432.CCR-16-0772","article-title":"Phase I study of the anti-CD22 antibody-drug conjugate pinatuzumab vedotin with\/without rituximab in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"23","author":"Advani","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tips.2025.11.004_bb0445","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1158\/1078-0432.CCR-15-2488","article-title":"Phase I study of inotuzumab ozogamicin combined with R-CVP for relapsed\/refractory CD22+ B-cell non-Hodgkin lymphoma","volume":"22","author":"Ogura","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tips.2025.11.004_bb0450","first-page":"672","article-title":"(227)Th-labeled anti-CD22 antibody (BAY 1862864) in relapsed\/refractory CD22-positive non-Hodgkin lymphoma: a first-in-human, Phase I study","volume":"36","author":"Linden","year":"2021","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.tips.2025.11.004_bb0455","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.4049\/jimmunol.2100820","article-title":"SM03, an anti-CD22 antibody, converts cis-to-trans ligand binding of CD22 against alpha2,6-LINKED sialic acid glycans and immunomodulates systemic autoimmune diseases","volume":"208","author":"Wong","year":"2022","journal-title":"J. Immunol."},{"key":"10.1016\/j.tips.2025.11.004_bb0460","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/10428194.2021.1966780","article-title":"A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas","volume":"63","author":"Pirosa","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.tips.2025.11.004_bb0465","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0140-6736(24)00746-3","article-title":"CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study","volume":"404","author":"Frank","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2025.11.004_bb0470","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1186\/s12967-025-06567-3","article-title":"Efficacy and safety of a novel CD19, CD22 dual-targeted fully human loop bi-CAR-T for the treatment of relapsed\/refractory B cell non-Hodgkin lymphoma","volume":"23","author":"Wang","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.tips.2025.11.004_bb0475","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1200\/JCO.20.03048","article-title":"Gemtuzumab ozogamicin improves event-free survival and reduces relapse in pediatric KMT2A-rearranged AML: results from the Phase III Children's Oncology Group Trial AAML0531","volume":"39","author":"Pollard","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tips.2025.11.004_bb0480","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1200\/JCO.2016.71.2513","article-title":"CD33 splicing polymorphism determines gemtuzumab ozogamicin response in de novo acute myeloid leukemia: report from randomized Phase III Children's Oncology Group Trial AAML0531","volume":"35","author":"Lamba","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tips.2025.11.004_bb0485","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13742","article-title":"First-in-human study of JNJ-67571244, a CD33 x CD3 bispecific antibody, in relapsed\/refractory acute myeloid leukemia and myelodysplastic syndrome","volume":"17","author":"Narayan","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.tips.2025.11.004_bb0490","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/10428194.2024.2346755","article-title":"Safety and tolerability of AMG 330 in adults with relapsed\/refractory AML: a phase 1a dose-escalation study","volume":"65","author":"Ravandi","year":"2024","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.tips.2025.11.004_bb0495","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1038\/s41375-021-01232-2","article-title":"Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia","volume":"35","author":"Tambaro","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.tips.2025.11.004_bb0500","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1136\/annrheumdis-2012-202760","article-title":"Efficacy and safety of epratuzumab in patients with moderate\/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study","volume":"73","author":"Wallace","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.tips.2025.11.004_bb0505","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40261-016-0426-7","article-title":"Pharmacokinetics, pharmacodynamics and preliminary observations for clinical activity and safety of multiple doses of human mouse chimeric anti-CD22 monoclonal antibody (SM03) in Chinese patients with systemic lupus erythematosus","volume":"36","author":"Zhao","year":"2016","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.tips.2025.11.004_bb0510","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/art.39856","article-title":"Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two Phase III randomized, double-blind, placebo-controlled trials","volume":"69","author":"Clowse","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.tips.2025.11.004_bb0515","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1093\/rheumatology\/keab699","article-title":"SM03, an anti-human CD22 monoclonal antibody, for active rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled study","volume":"61","author":"Li","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.tips.2025.11.004_bb0520","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nri1838","article-title":"B-cell targeting in rheumatoid arthritis and other autoimmune diseases","volume":"6","author":"Edwards","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tips.2025.11.004_bb0525","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.3389\/fimmu.2018.02235","article-title":"CD22: a regulator of innate and adaptive B cell responses and autoimmunity","volume":"9","author":"Clark","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tips.2025.11.004_bb0530","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/bjd\/ljad191","article-title":"Safety and efficacy of lirentelimab in patients with refractory indolent systemic mastocytosis: a first-in-human clinical trial","volume":"189","author":"Siebenhaar","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.tips.2025.11.004_bb0535","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126219","article-title":"Siglec-8 antibody reduces eosinophils and mast cells in a transgenic mouse model of eosinophilic gastroenteritis","volume":"4","author":"Youngblood","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.tips.2025.11.004_bb0540","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000501637","article-title":"AK002, a humanized sialic acid-binding immunoglobulin-like lectin-8 antibody that induces antibody-dependent cell-mediated cytotoxicity against human eosinophils and inhibits mast cell-mediated anaphylaxis in mice","volume":"180","author":"Youngblood","year":"2019","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.tips.2025.11.004_bb0545","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1056\/NEJMoa2012047","article-title":"Anti-Siglec-8 antibody for eosinophilic gastritis and duodenitis","volume":"383","author":"Dellon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2025.11.004_bb0550","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1158\/1078-0432.CCR-19-2925","article-title":"Siglec-15 as an emerging target for next-generation cancer immunotherapy","volume":"27","author":"Sun","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tips.2025.11.004_bb0555","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.3324\/haematol.2022.281128","volume":"107","author":"Fiedler","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.tips.2025.11.004_bb0560","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40364-022-00369-1","article-title":"The intriguing roles of Siglec family members in the tumor microenvironment","volume":"10","author":"Jiang","year":"2022","journal-title":"Biomark. Res."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614725002585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614725002585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:19:19Z","timestamp":1793895559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614725002585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":112,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0165614725002585"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2025.11.004","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Siglecs in immunotherapy: current clinical landscape and prospects","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2025.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}